Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
0.9000
-0.0011 (-0.12%)
Oct 19, 2026, 10:13 AM EDT - Market open
Cardiff Oncology Stock Forecast
CRDF's stock price has decreased by -62.61% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 7 analysts polled by S&P Global, Cardiff Oncology stock has a consensus rating of "Buy" and an average price target of $5.81. The average 1-year stock price forecast is 545.56% higher than the current stock price, while the lowest is $1.20 (+33.33%) and the highest is $12 (+1,233.33%).
Price Target: $5.81 (+545.56%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on Sep 15, 2026.
Analyst Ratings
The average analyst rating for Cardiff Oncology stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 3 | 1 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 4 | 4 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Craig-Hallum | Craig-Hallum | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Sep 15, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Upgrades $9 | Buy | Upgrades | $9 | +900.00% | Sep 15, 2026 |
| William Blair | William Blair | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Sep 14, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $6 | Buy | Reiterates | $6 | +566.67% | Aug 12, 2026 |
| TD Cowen | TD Cowen | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Aug 11, 2026 |
Financial Forecast
Revenue This Year
295.14K
from 593.00K
Decreased by -50.23%
Revenue Next Year
320.83K
from 295.14K
Increased by 8.70%
EPS This Year
-0.56
from -0.69
EPS Next Year
-0.54
from -0.56
EPS and Forward PE are based on non-GAAP adjusted numbers.